A detailed history of Marathon Capital Management transactions in Ani Pharmaceuticals Inc stock. As of the latest transaction made, Marathon Capital Management holds 70,045 shares of ANIP stock, worth $3.96 Million. This represents 1.05% of its overall portfolio holdings.

Number of Shares
70,045
Previous 70,295 0.36%
Holding current value
$3.96 Million
Previous $4.48 Million 6.66%
% of portfolio
1.05%
Previous 1.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$54.33 - $65.72 $13,582 - $16,430
-250 Reduced 0.36%
70,045 $4.18 Million
Q2 2024

Aug 14, 2024

SELL
$58.53 - $68.82 $51,213 - $60,217
-875 Reduced 1.23%
70,295 $4.48 Million
Q1 2024

May 15, 2024

BUY
$54.2 - $69.69 $73,170 - $94,081
1,350 Added 1.93%
71,170 $4.92 Million
Q4 2023

Feb 08, 2024

SELL
$48.72 - $65.43 $90,132 - $121,045
-1,850 Reduced 2.58%
69,820 $3.85 Million
Q3 2023

Nov 14, 2023

BUY
$50.28 - $64.61 $152,097 - $195,445
3,025 Added 4.41%
71,670 $4.16 Million
Q2 2023

Aug 14, 2023

SELL
$37.29 - $53.83 $605,776 - $874,468
-16,245 Reduced 19.14%
68,645 $3.7 Million
Q1 2023

May 12, 2023

BUY
$37.61 - $45.72 $451,320 - $548,640
12,000 Added 16.46%
84,890 $3.37 Million
Q3 2022

Nov 14, 2022

SELL
$29.83 - $38.01 $46,833 - $59,675
-1,570 Reduced 2.11%
72,890 $2.34 Million
Q2 2022

Aug 12, 2022

SELL
$23.09 - $33.46 $12,699 - $18,403
-550 Reduced 0.73%
74,460 $2.21 Million
Q1 2022

May 13, 2022

BUY
$26.91 - $47.15 $6,458 - $11,316
240 Added 0.32%
75,010 $2.11 Million
Q4 2021

Feb 09, 2022

BUY
$32.97 - $56.85 $18,957 - $32,688
575 Added 0.77%
74,770 $3.45 Million
Q3 2021

Nov 15, 2021

BUY
$26.48 - $35.99 $1.96 Million - $2.67 Million
74,195 New
74,195 $2.44 Million

Others Institutions Holding ANIP

About ANI PHARMACEUTICALS INC


  • Ticker ANIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 17,426,000
  • Market Cap $986M
  • Description
  • ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose produc...
More about ANIP
Track This Portfolio

Track Marathon Capital Management Portfolio

Follow Marathon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Marathon Capital Management with notifications on news.